Organigram Reports Record Third Quarter Fiscal 2026 Results
Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) reported Q3 fiscal 2026 results for the quarter ended June 30, 2026. Gross revenue rose to $145.1M (+32% YoY), net revenue to $105.8M (+49%), and adjusted EBITDA to $13.4M (+136%). Net income was $105.5M. Results were driven largely by Sanity Group GmbH, acquired April 15, 2026.
How this was made
The 30-second read
Why it matters
The key trading signal is acquisition-driven earnings power (adjusted EBITDA +136% YoY) alongside margin improvement, plus management guidance for net revenue to exceed $350M and an expectation of positive FCF in Q4 despite modestly negative full-year FCF.
Market read
This is a company-specific earnings release with hard financials and explicit forward-looking targets, likely driving same-day repricing and positioning for the remaining quarter.
What to watch
Working-capital investment is expected to keep full-year FCF modestly negative, and the cash decline (cash & short-term investments down vs Sept 30, 2025) may raise questions about liquidity and conversion.
Background
Organigram’s Q3 FY2026 results are the first quarter with financial contributions from its Sanity Group GmbH acquisition (closed April 15, 2026).
Ticker impact
Organigram reported Q3 FY2026 revenue of $145.1M (+32% YoY) and adjusted EBITDA of $13.4M (+136% YoY) driven by Sanity Group contributions.
Near-term bias positive as traders price in acquisition-driven earnings power, but watch for skepticism around cash generation given FCF outflow and declining cash balances.
The article provides multiple hard financial datapoints (revenue, net revenue, adjusted EBITDA, margins, FCF) and a forward-looking statement (net revenue > $350M; positive FCF in Q4) tied to the acquisition and working capital.
Market effects
Cannabis equities may see read-across interest as acquisition-led margin expansion and international rollout progress are highlighted.
Canada-focused cannabis demand and category leadership claims could support sentiment toward Canadian licensed producers.
European expansion milestones (Switzerland, Poland, UK partnerships) reinforce the theme of cross-border consolidation in cannabis platforms.
Counterpoint
Despite record adjusted EBITDA, free cash flow was negative in the quarter and cash balances fell sharply, which could temper valuation support.
Key entities
- companyOrganigram Global Inc.
Reported Q3 FY2026 record revenue and adjusted EBITDA, attributing gains primarily to Sanity Group contributions.
- companySanity Group GmbH
Acquired entity whose European growth execution is cited as contributing about €25M (C$40M) net revenue in the quarter.
- personJames Yamanaka
CEO quoted on acquisition milestone, Canadian resilience, and execution into the final quarter of FY2026.
- personGreg Guyatt
CFO quoted on margin profile, net revenue target, and working-capital-driven FCF expectations.
